Loading…
Adagene Inc. is projected to rise to $4.23 by 2027, a +13% move from its current price of $3.75. ADAG is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $3.61 | $3.75 | $3.90 | +0.04% |
| Aug 4 | $3.55 | $3.75 | $3.97 | +0.07% |
| Aug 5 | $3.51 | $3.75 | $4.02 | +0.11% |
| Aug 6 | $3.47 | $3.76 | $4.06 | +0.14% |
| Aug 7 | $3.44 | $3.76 | $4.10 | +0.18% |
| Aug 8 | $3.41 | $3.76 | $4.14 | +0.22% |
| Aug 9 | $3.39 | $3.76 | $4.17 | +0.25% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.39 | $3.76 | $4.17 | +0.25% |
| Week 2 | $3.25 | $3.77 | $4.37 | +0.51% |
| Week 3 | $3.15 | $3.78 | $4.53 | +0.76% |
| Week 4 | $3.07 | $3.79 | $4.67 | +1.02% |
| Week 5 | $3.01 | $3.80 | $4.80 | +1.27% |
| Week 6 | $2.95 | $3.81 | $4.92 | +1.53% |
| Week 7 | $2.90 | $3.82 | $5.03 | +1.79% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Adagene Inc. is a clinical stage biotechnology company focused on researching, developing, and producing monoclonal antibody drugs for cancers in the People’s Republic of China. It operates in the Healthcare sector and was incorporated in 2011, with headquarters in Suzhou, China.
Its lead product candidate is ADG126, a masked fully-human anti-CTLA-4 mAb in phase 1b/2 clinical development for cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody in phase 2; and ADG125, a novel anti-CSF-1R mAb in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in preclinical trial to treat low expressing tumors, as well as ADG152, a CD20xCD3 POWERbody in preclinical trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical trial for the treatment of hematologic and solid tumors; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors.
Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
Adagene Inc. (ADAG) is currently priced at $3.53 with a market capitalization of $233.24M. It is ranked 3536 by market capitalization. The current price sits near the 50-day moving average of $3.74 and above the 200-day moving average of $2.92.
The 30-day price range spans from $2.73 to $4.57, with near-term support at $3.37 and resistance at $4.78. The forecast landscape suggests a long-term upside, with 2026 average price at $3.53 and progressively higher values in subsequent years, including a 2030 average of $6.31, a 2040 average of $12.17, and a 2050 average of $28.13.
A major floor 37.9% below — a decisive break under it would weaken the trend.
The nearest floor, 14.7% below — buyers have tended to step in here.
The nearest ceiling, 27.5% above — a clean break opens room to run.
A major ceiling 46.4% above — clearing it would confirm fresh momentum.
Key ADAG support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ADAG market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.69 | Buy | $3.68 | Buy |
| MA 10 | $3.59 | Buy | $3.66 | Buy |
| MA 20 | $3.68 | Buy | $3.69 | Buy |
| MA 50 | $3.75 | Sell | $3.72 | Buy |
| MA 100 | $3.77 | Sell | $3.57 | Buy |
| MA 200 | $2.97 | Buy | $3.18 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.10 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 31.90 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 2.18 | Buy |
| Bollinger %B (20,2) | 0.59 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.25 | Sell |
| Awesome (5,34) | -0.13 | Sell |
| Ultimate (7,14,28) | 54.29 | Neutral |
| Momentum (10) | 0.16 | Buy |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 3.81 | Sell |
| ADX (14) | 10.60 | Neutral |
| ATR (14) | 0.12 | Info |
The 30-day technical picture is NEUTRAL, with RSI (14) at 40. The 50-day simple moving average stands at $3.74, while the 200-day simple moving average is $2.92.
The 30-day range is $2.73 to $4.57, with near-term support at $3.37 and resistance at $4.78, framing a modestly range-bound near-term outlook.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.53 | $3.75 | $4.65 | 0% | Neutral | |
| $3.24 | $4.23 | $5.92 | +13% | Neutral | |
| $3.76 | $5.13 | $7.56 | +37% | Bullish | |
| $4.80 | $6.79 | $10.40 | +81% | Bullish | |
| $4.96 | $7.24 | $11.45 | +93% | Bullish | |
| $4.96 | $7.46 | $12.14 | +99% | Bullish | |
| $5.31 | $8.21 | $13.71 | +119% | Bullish | |
| $5.12 | $8.12 | $13.86 | +116% | Bullish | |
| $5.33 | $8.66 | $15.10 | +131% | Bullish | |
| $6.47 | $10.79 | $19.17 | +188% | Bullish | |
| $8.13 | $15.17 | $29.18 | +304% | Bullish | |
| $16.18 | $35.96 | $77.44 | +859% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.53 | $3.75 | $4.53 | +0.00% |
| September 2026 | $3.22 | $3.86 | $4.80 | +3.03% |
| October 2026 | $3.20 | $3.88 | $4.88 | +0.31% |
| November 2026 | $3.00 | $3.66 | $4.66 | -5.65% |
| December 2026 | $2.93 | $3.61 | $4.65 | -1.34% |
Click any year to see its month-by-month ADAG forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ADAG price prediction for 2026 points to an average of $3.75 (low $1.53, high $4.65) — a potential gain of 0% on today's $3.75. Price action looks broadly range-bound.
In 2027, ADAG is projected to trade between $3.24 and $5.92, averaging $4.23 — a potential gain of +13% from today's $3.75. That is up +13% on the projected 2026 average. A consolidation phase looks the most probable path here.
Adagene Inc.'s 2028 outlook centres on $5.13, within a $3.76 to $7.56 range. That is up +21% on the projected 2027 average. That marks a +37% change versus current levels. Momentum favours further upside here.
By 2029, ADAG could reach as high as $10.40, with a base case around $6.79 and support toward $4.80 — roughly +81% from $3.75. Buyers look set to stay in control over this stretch.
Expect ADAG to range from $4.96 to $11.45 through 2030. The $7.24 average target implies a +93% move from current prices. That is up +7% on the projected 2029 average. Momentum favours further upside here.
The ADAG price prediction for 2031 points to an average of $7.46 (low $4.96, high $12.14) — a potential gain of +99% on today's $3.75. Buyers look set to stay in control over this stretch.
In 2032, ADAG is projected to trade between $5.31 and $13.71, averaging $8.21 — a potential gain of +119% from today's $3.75. That is up +10% on the projected 2031 average. Momentum favours further upside here.
Adagene Inc.'s 2033 outlook centres on $8.12, within a $5.12 to $13.86 range. That is -1% versus the projected 2032 average. That marks a +116% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, ADAG could reach as high as $15.10, with a base case around $8.66 and support toward $5.33 — roughly +131% from $3.75. Momentum favours further upside here.
Expect ADAG to range from $6.47 to $19.17 through 2035. The $10.79 average target implies a +188% move from current prices. That is up +25% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The ADAG price prediction for 2040 points to an average of $15.17 (low $8.13, high $29.18) — a potential gain of +304% on today's $3.75. Momentum favours further upside here.
In 2050, ADAG is projected to trade between $16.18 and $77.44, averaging $35.96 — a potential gain of +859% from today's $3.75. That is up +137% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ADAG today (≈ 266.666667 ADAG) could be worth
$9,588.58
+$8,588.58 (+859%) by 2050 · US Dollar
Based on the average projected ADAG price of $35.96 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ADAGwould be worth at today's price.
$1,000 invested in ADAG on Jul 31, 2025 (≈ 502.51256 ADAG) would be worth
$1,884.42
+$884.42 (+88.4%) today · 1.88× · US Dollar
Based on a ADAG entry price of $1.99 vs. today's $3.75.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.2 | $1,171.87 | +17.2% |
| 1 month ago | $4.78 | $784.52 | -21.5% |
| 3 months ago | $3.82 | $981.68 | -1.8% |
| 6 months ago | $2.94 | $1,275.51 | +27.6% |
| 1 year ago | $1.99 | $1,884.42 | +88.4% |
| All time (5.0y) ago | $16.74 | $224.01 | -77.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ADAG forecast.
Our base-case forecast reaches $7.50 around 2032.
Implied market cap at $7.50: $495.54M
The multi-year forecast shows an overarching bullish trajectory over time. For 2026, the min is $1.53, the avg is $3.53, and the max is $4.37, with ROI 0 and sentiment NEUTRAL. Looking further, 2030 forecasts an avg of $6.31 with ROI 78.8, 2040 forecasts an avg of $12.17 with ROI 244.8, and 2050 forecasts an avg of $28.13 with ROI 697, all indicating meaningful upside potential in the long run.
These projections imply substantial appreciation from current levels, albeit as estimates subject to development milestones, regulatory actions, and broader market conditions. The numbers show a clear path to higher prices in later years, but they are not guarantees and should be interpreted with appropriate caution.
Tap a question to reveal the answer.
In 2030, the forecast shows min $4.33, avg $6.31, max $9.97, with ROI 78.8 and bullish sentiment.
Forecasts indicate a bullish path in later years with rising averages and ROIs (e.g., 2027 avg $3.86; 2028 avg $4.51; 2029 avg $5.98; 2030 avg $6.31 with ROI 78.8), but these are estimates and not guarantees.
Yes, the forecast shows potential above $10 in 2031-2034, with 2031 max $10.41, 2032 max $11.79, 2033 max $11.65, and 2034 max $12.39.
The current price is $3.53 and the market capitalization is $233.24M.
The 30-day range is $2.73 to $4.57.
Adagene Inc. Community Discussion
0Share your Adagene Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.